Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Full session details can be accessed on the ACAAI website. The poster will be available on the publications page of the Apogee website on October 24.

The connection between respiratory infections, chronic diseases like asthma, and the gut microbiome drives research toward ...

causing inflammation and reduced lung function. Urban dwellers face higher risks due to increased exposure from vehicles, ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

Steroid tablets are associated with significant adverse side effects. Short-term use risks sleep disturbance, reflux, ...

It is important to try and target treatments to disrupt pathobiologic processes that give rise to pathophysiologic patterns in asthma, COPD and ACOS. Small airway inflammation and smooth muscle ...

The Asthma Society of Ireland has warned that over-use of steroid medication may cause more harm than good. A study has shown ...

COPD is an inflammatory respiratory condition that ... Amgen and AstraZeneca have hopes for their asthma drug Tezspire as a potential treatment for COPD, as it has shown effectiveness in treating ...